background: recurrent upper respiratory infections (rUri) constitute a social problem for both their pharmaco-economic impact and the burden for the family. Bacteriotherapy could be an interesting preventive option.
IntrODuctIOn
Upper respiratory infections (URI) during infancy and childhood are a relevant issue (1, 2) . As many children suffer from recurrent URI (RURI), it determines a relevant impact on pharmaco-economy and is a burden for both the family and the society (2, 3) . So, RURI represents a challenge for both the paediatrician and the otolaryngologist.
Many factors may be involved in promoting and/or causing RURI, including early age (for a relative immaturity of the immune system), early attendance at nursery school, air and home pollution, passive smoking, low socio-economic level, and atopy (2) . In addition, viral infections may increase the probability of contracting frequent RI because of the high number of circulating viruses and numerous sub-types (3) . Usually, viral infections are predominant, but bacterial over-infections may also frequently appear.
In common practice, the diagnosis of URI is usually based on a clinical ground, such as consideration of the clinical history, and the presence of typical signs and symptoms. As punctually pointed out by guidelines, treatment includes anti-inflammatory drugs and antibiotics prescribed on an empiric basis (3, 4) . On the other hand, anti-inflammatory agents may have relevant side effects, mainly in children. In addition, antibiotic overuse is frequently associated with the outgrowth of multi-resistant microbes. Actually, effective RURI preven-original article 24SMB), administered by nasal spray, had the capability to reduce the risk of new episodes of acute otitis media (AOM) in otitis-prone children (6) . The results were promising, so a further study was successful in demonstrating that Streptococcus salivarius 24SMB associated with Streptococcus oralis89a administered as nasal spray in children suffering from recurrent AOM was effective in preventing recurrent otitis in a real-life setting (7) . However, no clinical study evaluated the capacity of this combined Bacteriotherapy in children with RURI. Therefore, the present real-world study aimed to evaluate the potion might significantly affect risk of complications, medical costs, and social and family impact. On the other hand, many past attempts of prevention were tried, but they were usually expensive, long-lasting, and seldom fruitless or accompanied by adverse events. Therefore, preventing RURI using alternative ways might represent an interesting and stimulating issue. In this regard, an intriguing topic has been highlighted by the investigation of the upper airways microbiome (5). The physiological nasopharyngeal microbiome does physiologically inhibit the growth of local pathogens. So, it has been hypothesized that the administration of ‚good' bacteria could exert preventive effects on infections as it might wipe out pathogens. Some years ago, it was demonstrated that an α-haemolytic strain, obtained from healthy children (Streptococcus salivarius with RURI were enrolled in the study. Inclusion criteria were: i) age ranging between 3 and 14 years, ii) both genders, iii) documented history of RURI in the past year, iv) written informed consent by parents. Exclusion criteria were: i) severe allergic symptoms (able to interfere the assessment of treatments), ii) congenital or acquired immunodeficiency, iii) craniofacial abnormalities, iv) sleep apnoea, v) Down syndrome, vi) chronic disease (including metabolic disorders, cystic fibrosis, cancer, etc.), vii) clinically relevant passive smoking, ssible preventive effect of this Bacteriotherapy in a cohort of children suffering from RURI.
MAterIAls AnD MethODs
Population and eligibility criteria original article
Statistical analysis
Demographic and clinical characteristics are described using means with SDs for normally-distributed continuous data (i. 
results
All treatments were well tolerated and no clinically relevant side effect was observed.
Analysis of the whole population
The present study analysed the reports of 80 outpatients. Demographic and clinical characteristics are reported in Table I . The number of URI episodes strongly correlated with the number of school days missed per month (r = 0.678, p<0.001, Figure  4A ). Similarly, a moderate correlation was detected between the number of URI episodes and the number of working days missed per month (r = 0.514, p<0.001, Figure 4B ). As expected, the number of school days missed per month strongly correlated with the number of working days missed per month (r = 0.601, p<0.0001, Figure 5 ).
and viii) previous (last 3 months) or current administration of drugs able to interfere with the study (e.g., immunomodulant, homeopathic therapy, or systemic corticosteroids for at least 2 consecutive weeks).
Study design
The current study was designed as retrospective and observational. Children with URI were initially visited by primary care paediatricians who sent them to the otolaryngologists for thorough management. Children were treated with a commercially available class IIa medical device nasal spray containing Streptococcus salivarius 24SMB and Streptococcus oralis 89a (Rinogermina nasal spray, DMG, Rome, Italy). It was administered in 2 puffs per nostril twice/day for 7 days. The suspension consisted of a minimum of 109 colony forming unit per dose. This course was usually administered for 3 consecutive months. As Bacteriotherapy has a preventive activity, the course usually started in early autumn.
The evaluated parameters were: the number of URI, and the number of days of school or work (for parents) absence in the past. These variables were evaluated in the past year and at follow-up re-evaluation. In addition, siblings' presence, and passive smoking were evaluated.
Safety
Safety and tolerability were evaluated on the basis of the number and type of adverse events recorded according to the rules of good clinical practice.
Study procedures
The investigators diagnosed URI on the basis of the symptoms reported by the parents, as previously defined (8) . RI diagnosis was made when at least 2 symptoms or fever (axillary temperature >38°C), in addition to one other symptom, were present for at least 48 hours. The symptoms taken into consideration for this diagnostic purpose were: mucopurulent rhinorrhoea, stuffy or dripping nose or both, sore-throat, cough (dry or productive), otalgia (earache), fever, and mucopurulent secretion. RURI diagnosis was performed based on history, such as patient's recall of symptoms.
The children were examined at study entry, and at follow-up re-evaluation (in the summer). The study started in September 2016 and ended in June 2017.
All assessed parameters were regularly recorded in a daily diary card.
potential preventive effect of a 12-month treatment with azithromycin (5mg/Kg/d) 3 d/wk in children with RRS (10,11). Actually, azithromycin prophylaxis reduced the number of ARS episodes, the medication score, and respiratory symptoms. However, this preventive proposal is very long-lasting and could easily induce the occurrence of resistance to macrolides. Macrolides resistance is an emerging problem in many European countries, including Italy (12). So, it seems better to consider alternative ways. Bacteriotherapy, such as the use of ‚good' bacteria, may be a promising preventive strategy. In fact, the rationale is based on the demonstration that some non-pathogenic strains may protect from bacterial infections. Indeed, the current study, conducted in a real-life setting, shows that Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray may be a reliable option in RURI prevention. Off note, no side effects were reported, so the compound was safe and well tolerated by all treated children. The main outcomes of the current study provided evidence that Bacteriotherapy significantly diminished the number of URI and consistently, school and work absences. Notably, Bacteriotherapy was more effective in children with frequent RURI, such as >6/year. This issue underlines the clinical relevance of the present findings.
However, this study has some limitations: i) to be an open study, ii) to be without a control-placebo group, iii) to be based only on clinical outcomes without cultural investigations, and iv) data concerning the past year were retrospectively collected by parents' queries. Thus, further studies should be conducted to correctly define the unmet needs.
In conclusion, the current real-life study demonstrated that Streptococcus salivarius 24SMB and Streptococcus oralis 89a nasal spray could be effective in preventing RURI in children.
No correlations were found between changes in the number of URI episodes after Bacteriotherapy and the age at the beginning of treatment (r = 0.076, p = 0.50, not shown).
Moreover, sibling presence and allergy did not affect any result. Passive smoking was significantly associated only with school absence (p=0.02).
Comparison between patients with high or low number of URI episodes in the year preceding treatment
Patients were subdivided in two sub-groups on the basis of the number of URI episodes in the year preceding the study: > 6 or < 6.
The reduction in the number of URI episodes after treatment and in the number of school days or working days missed per month was higher for patients with a high number of URI episodes (i.e. >6 episodes) in the year preceding treatment than in those with a low number of URI episodes (i.e. <6 episodes) in the year preceding treatment (p<0.001, each comparison) as reported in Table II .
DIscussIOn
RURI represents a demanding challenge for both the ENT specialist and the paediatrician. The therapy is suggested by guidelines that limit antibiotic prescription to more demanding infections. However, in the clinical practice, antibiotics are frequently prescribed, ignoring guidelines precepts. In addition, prevention of RURI is even more debated. In this regard, a very recent placebo-controlled study investigated the
